SBRA
Sabra Health Care REIT, Inc. Real Estate - Healthcare Facilities Investor Relations →
Sabra Health Care REIT, Inc. (SBRA) closed at $18.12 as of 2026-06-19, trading 29.2% above its 200-week moving average of $14.03. The stock is currently moving closer to the line, down from 33.8% last week. The 14-week RSI sits at 34, indicating neutral momentum.
Trading volume is running at 1.8x of its 14-week average, which is in the normal range. The balance between buying and selling volume (0.77 ratio) is neutral — neither side is clearly dominating.
Over the past 1215 weeks of data, SBRA has crossed below its 200-week moving average 25 times. On average, these episodes lasted 20 weeks. Historically, investors who bought SBRA at the start of these episodes saw an average one-year return of +180.5%.
With a market cap of $4.6 billion, SBRA is a mid-cap stock. The company generates a free cash flow yield of 4.3%. Return on equity stands at 5.7%. The stock trades at 1.6x book value.
Share count has increased 9.0% over three years, indicating dilution.
Over the past 23.3 years, a hypothetical investment of $100 in SBRA would have grown to $15200, compared to $1353 for the S&P 500. That represents an annualized return of 24.0% vs 11.8% for the index — confirming SBRA as a market-beating investment and the kind of quality company where buying during 200-week moving average touches has historically been rewarded.
Free cash flow has been growing at a 3.4% compound annual rate, with 4 consecutive years of positive cash generation.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: SBRA vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After SBRA Crosses Below the Line?
Across 25 historical episodes, buying SBRA when it crossed below its 200-week moving average produced an average return of +297.8% after 12 months (median +14.0%), compared to +16.6% for the S&P 500 over the same periods. 56% of those episodes were profitable after one year. After 24 months, the average return was +200.5% vs +33.6% for the index.
Each line shows $100 invested at the moment SBRA crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Bean Score Experimental
The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. Between earnings dates, FCF is constant — so the score is purely a function of stock price. The levels below show at what prices SBRA would reach each dislocation threshold.
Dislocation Price Levels
Prices where SBRA's Bean Score would hit each σ threshold. Valid until next earnings report: 2026-04-29.
| Level | σ | Price | Signal |
|---|---|---|---|
| Deep Value | +2σ | $18.81 | Unusually cheap — potential buy zone |
| Value | +1σ | $19.46 | Cheap vs. own history |
| Fair Value | +0σ | $20.16 | Historical mean behavior |
| Expensive | -1σ | $20.91 | Expensive vs. own history |
| Deep Expensive | -2σ | $21.72 | Unusually expensive — potential trim zone |
Quarterly FCF & Yield Trailing twelve-month free cash flow and yield at each quarter end
Signal Accuracy Collecting Data
The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"
Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are reference points for identifying potential swing trade opportunities, not buy/sell signals. FCF values update quarterly with earnings; between reports, all movement is price-driven.
Dislocation Scores Experimental
Each score measures deviation from SBRA's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.
Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. They are starting points for research, not buy or sell signals. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.
Historical Touches
SBRA has crossed below its 200-week MA 25 times with an average 1-year return of +180.5% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Mar 2003 | Sep 2003 | 26 | 98.4% | +4183.3% | +7500.2% |
| May 2004 | May 2004 | 1 | 9.2% | -7.3% | +240.8% |
| Jun 2004 | Jun 2004 | 1 | 2.1% | -14.6% | +214.5% |
| Jul 2004 | Aug 2004 | 4 | 8.6% | -8.7% | +235.3% |
| Oct 2004 | Nov 2004 | 2 | 1.1% | +8.6% | +208.1% |
| Nov 2004 | Dec 2004 | 4 | 5.6% | +4.2% | +223.0% |
| Feb 2005 | Oct 2005 | 34 | 19.3% | -15.3% | +204.0% |
| Nov 2005 | Nov 2005 | 1 | 0.3% | +47.1% | +209.8% |
| Dec 2005 | Mar 2006 | 12 | 15.7% | +73.3% | +232.9% |
| Oct 2008 | Oct 2008 | 1 | 1.7% | -12.6% | +106.7% |
| Nov 2008 | Feb 2009 | 12 | 24.0% | -20.1% | +112.1% |
| Feb 2009 | Jul 2012 | 177 | 63.0% | -0.6% | +155.0% |
| Sep 2015 | Oct 2015 | 1 | 0.0% | +22.2% | +94.7% |
| Oct 2015 | Jul 2016 | 38 | 32.3% | +10.5% | +92.7% |
| Oct 2016 | Nov 2016 | 4 | 9.9% | +1.2% | +95.8% |
| Aug 2017 | Aug 2017 | 3 | 7.4% | +13.2% | +77.2% |
| Sep 2017 | May 2018 | 34 | 21.6% | +16.2% | +70.4% |
| Nov 2018 | Nov 2018 | 2 | 5.3% | +28.7% | +81.7% |
| Dec 2018 | Jan 2019 | 5 | 14.2% | +19.7% | +77.1% |
| Feb 2019 | Mar 2019 | 3 | 5.6% | +20.1% | +83.0% |
| Mar 2020 | Nov 2020 | 36 | 50.5% | +87.5% | +184.4% |
| Aug 2021 | Aug 2021 | 1 | 3.8% | +13.2% | +75.2% |
| Sep 2021 | Jul 2022 | 43 | 22.8% | -4.4% | +73.9% |
| Sep 2022 | Jul 2023 | 44 | 22.7% | +6.1% | +74.8% |
| Jul 2023 | Aug 2023 | 4 | 6.4% | +40.4% | +76.8% |
| Average | 20 | — | +180.5% | — |
Frequently Asked Questions
Is SBRA below its 200-week moving average?
No. Sabra Health Care REIT, Inc. (SBRA) is currently 29.2% above its 200-week moving average of $14.03. It would need to fall to $14.03 to cross below the line.
What is SBRA's 200-week moving average price?
Sabra Health Care REIT, Inc.'s 200-week moving average is $14.03 as of 2026-06-19. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when SBRA drops below its 200-week moving average?
SBRA has crossed below its 200-week moving average 25 times in our data. On average, buying at that moment produced a one-year return of +180.5%. These dips have historically been decent entry points. These episodes lasted 20 weeks on average.
Is SBRA a good value right now?
Here's what our data says about SBRA as of 2026-06-19: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 34. Free cash flow yield is 4.3%. Return on equity is 5.7%. Price-to-book is 1.6x. This is not a buy or sell recommendation — always do your own research.
How does SBRA compare to the S&P 500?
Over the past 23.3 years, $100 invested in SBRA would have grown to $15200, compared to $1353 for the S&P 500. That's 24.0% annualized vs 11.8% for the index. SBRA has outperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-06-19